UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000010721
Receipt number R000012527
Scientific Title Assessment of efficacy and safety of continouation maintenance therapy with gemcitabine after cisplatin-gemcitabine induction chemotherapy in advanced squamous cell lung cancer (KTORG1302)
Date of disclosure of the study information 2013/05/15
Last modified on 2016/11/15 17:42:51

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Assessment of efficacy and safety of continouation maintenance therapy with gemcitabine after cisplatin-gemcitabine induction chemotherapy in advanced squamous cell lung cancer (KTORG1302)

Acronym

Assessment of efficacy and safety of CDDP+GEM followed by GEM in advanced squamous cell lung cancer

Scientific Title

Assessment of efficacy and safety of continouation maintenance therapy with gemcitabine after cisplatin-gemcitabine induction chemotherapy in advanced squamous cell lung cancer (KTORG1302)

Scientific Title:Acronym

Assessment of efficacy and safety of CDDP+GEM followed by GEM in advanced squamous cell lung cancer

Region

Japan


Condition

Condition

squamous cell lung cancer

Classification by specialty

Pneumology

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To evaluate the efficacy and the safety of continuation maintenance therapy with gemcitabine after cisplatin-gemcitabine induction chemotherapy in advanced squamous cell lung cancer

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2

Explanatory

Developmental phase

Phase II


Assessment

Primary outcomes

Progression Free Survival

Key secondary outcomes

Overall survival
Safety
response rate


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Induction chemotherapy(4 courses)
Gemcitabine(GEM):1000mg/m2, day1,8
Cisplatin(CDDP):80mg/m2, day1

contunuation meintenance chemotherapy(until PD)
Gemcitabine(GEM):1000mg/m2 day1,8

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

75 years-old >

Gender

Male and Female

Key inclusion criteria

1) Patients with histologically proven squamous cell lung cancer
2) No prior chemotherapy for squamous cell lung cancer or one year after operation or adjuvant chemotherapy
3) Age 20 to 75 years
4) Performance status(ECOG) 0 or 1
5) Measurable disease according to RECIST ver 1.1
6) Sufficient organ functions
7) Life expectancy of more than 3 months
8) Written informed consent

Key exclusion criteria

1) Patients with histologically proven non-squamous cell lung cancer
2) Recognized ILD or pulmonary fibrosis on X-rays
3) Pleural effusion, peritoneal fluid and pericardial fluid that need treatment
4) Superior vena cava syndrome
5) Symptomatic brain metastasis
6) Active concomitant malignancy
7) Prior therapy with gemcitabine
8) Diabetes and hypertension that cannot be controlled
9) Liver cirrhosis
10) Symptomatic or asymptomatic but treated heart disease
11) Severe infectious disease
12) Pregnant women, possibly pregnant women, wishing to become pregnant
13) Serious drug hypersensitivity or a history of drug allergy
14) Refusal of supportive care such as blood transfusion
15) Bleeding tendency
16) Other conditions not suitable for this study

Target sample size

60


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Hiroshige Yoshioka

Organization

Kurashiki Central Hospital (Ohara HealthCare Foundation)

Division name

Department of Respiratory Medicine

Zip code


Address

1-1-1 Miwa, Kurashiki City, Okayama, 710-8602 JAPAN

TEL

086-422-0210

Email

hirotin@kchnet.or.jp


Public contact

Name of contact person

1st name
Middle name
Last name Satoshi Ikeda

Organization

Kurashiki Central Hospital (Ohara HealthCare Foundation)

Division name

Department of Respiratory Medicine

Zip code


Address

1-1-1 Miwa, Kurashiki City, Okayama, 710-8602 JAPAN

TEL

086-422-0210

Homepage URL


Email

si13546@kchnet.or.jp


Sponsor or person

Institute

Kyoto Thoracic Oncology Research Group (KTORG)

Institute

Department

Personal name



Funding Source

Organization

None

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

兵庫県立尼崎病院(兵庫県)、大津赤十字病院(滋賀県)、京都桂病院(京都府)、北野病院(大阪府)、神戸市立医療センター中央市民病院(兵庫県)、神戸市立医療センター西市民病院(兵庫県)、大阪府済生会中津病院(大阪府)、福井赤十字病院(福井県)、姫路医療センター(兵庫県)、神鋼病院(兵庫県)、京都医療センター(京都府)、彦根市立病院(滋賀県)、市立長浜病院(滋賀県)、倉敷中央病院(岡山県)、京都大学附属病院(京都府)、民医連京都中央病院(京都府)


Other administrative information

Date of disclosure of the study information

2013 Year 05 Month 15 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Open public recruiting

Date of protocol fixation

2013 Year 04 Month 11 Day

Date of IRB


Anticipated trial start date

2013 Year 05 Month 15 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2013 Year 05 Month 14 Day

Last modified on

2016 Year 11 Month 15 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000012527


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name